Amgen drug approved to help cancer patients

Reduces risk of bone complicatoins

An Amgen-created drug received the green light last month for use by cancer patients to reduce the risk of bone complications.

Denosumab, brand name XGEVA, was approved by the U.S. Food and Drug Administration on Nov. 18.

This is the second FDA approval for the generic denosumab in the past six months. In June, the FDA approved the protein to treat osteoporosis in post-menopausal women.

In most people who die of cancer, malignant cells have spread, or metastasized, from one part of the b...

Oops! An active online subscription is required to access this content.

Please login below or Subscribe today!